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Eugenol (EU) and ibuprofene (IBU) were covalently bound to a bi-functionalized PEG, used as molecular carrier of drugs and the 
release kinetics of the two bioactive molecules was studied in vitro in buffer solution at pH 7.4, in simulated gastric fluid and in mouse 
plasma. The hydrolysis studies showed a specific cleavage dependent on the pH of the medium and by the presence of proteolytic 
enzymes in mouse plasma. Studies in vitro on the release of the parent drug from this double prodrug in various media, indicate that the 
adduct may be sufficiently stable to pass intact the gastrointestinal tract and release into the circulation EU and IBU. Many advantages 
may be achieved by the synthesis of the prodrug EU-PEG-IBU related to synergistic analgesic and anti-inflammatory effects, to the 
reduction of the adverse reactions and the improvement of the chemical-physical properties of the parent drugs.
Abstract
The PEGylation is defined as the covalent attachment of poly(ethylene glycol) (PEG) chains to bioactive substances. PEGylation 
has been investigated as drug delivery systems (DDS) for low molecular weight drugs but in this field, despite some interesting 
results, it has not reached the same success of protein PEGylation. Nevertheless, the development of PEG-small drug conjugates, 
especially those bearing a targeting residue or a combination of two drugs, is an intense area of research [1]. Methoxy PEG, CH3O–
(CH2CH2O)n–H, is at the basis of all approved PEGylated products either in its linear or branched form. Two key properties of this 
polymer are its great flexibility, owing to the absence of bulky substituents along the chain, and the high hydration of the polymeric 
backbone. Being nontoxic, non-immunogenic, non-antigenic and amphiphilic, PEG has been approved by FDA for human oral, 
intravenous, and dermal pharmaceutical applications [2].
                                 ISSN: 2348-9782
The conjugation of simple drugs or more complex molecules in synthetic polymers is of great interest in pharmacological 
applications. The PEG polymer is one of the most widely used for its chemical-physical and biological characteristics in the 
synthesis of prodrugs [3].
Generally, the design of a prodrug involves the optimization of drug release. A prodrug is a biologically inactive derivative of a 
drug that usually requires an enzymatic transformation in vivo in order to release the active principle. The use of PEG conjugates 
and the in vivo release of bioactive molecules has been extensively studied and many practical applications have been found. Other 
advantages of PEGylation are derived from the increased solubility of the prodrug that leads to a better distribution of the parent 
drug [4]. 
An increase of the water solubility, of the half-life time and a reduction of side effects of bioactive molecules can also be obtained 
through the preparation of polymeric prodrugs. The use of polymers as prodrugs of bioactive agents can reduce the required dose, 
and therefore the drug toxicity, improving its solubility and therapeutic effectiveness. Moreover, the conjugation to a polymer of a 
biologically active molecule is one of several methods to modify and control the pharmacokinetics, biodistribution and often the 
toxicity of these compounds.
The nonsteroidal anti-inflammatory drugs (NSAIDs) are often poorly soluble in water and often cause gastrointestinal side effects 
such as stomach ulcers, bleeding and perforation. 
Ibuprofen, (R,S) [2-(4-isobutylphenyl) propionic acid] belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs), 
acts by inhibiting isoforms of cyclo-oxygenase (COX) 1 and 2. It is used to treat inflammatory rheumatoid diseases and relieves 
acute pain [5]. It is poorly soluble in water, commonly administered orally, is rapidly absorbed and reaches the maximum plasmatic 
concentration within 2 hours. However, it has a short biological half-life of 2 hours, which means that frequent doses are required 
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to maintain the therapeutic efficacy for prolonged periods of time [6]. Progression in the gastrointestinal (GI) side effects 
particularly stomach ulceration, bleeding and perforation are the main constraint in its use which is particularly due to local action 
exerted by direct contact of drug with gastric mucosa [7]. Thus free acidic group plays a key role in maintaining the effectiveness 
and producing the gastric ulceration [8]. In view of this, various approaches have been used to minimize side effects by masking 
free acidic group chemically with retaining the potency, like i) the synthesis of ester derivatives of ibuprofen as mutual prodrugs 
with naturally occurring phenolic and alcoholic compounds [9-11] or ii) the conjugation with PEG with an increase of solubility 
in water and a prolongation of the pharmacological effects [6].
Eugenol(4-allyl-2-methoxyphenol) is the main component of clove oil (Eugenia aromatic), and is mainly produced in Indonesia. 
It is widely used in perfumes, as antioxidant, drug, food, and taste items. It is practically insoluble in water and has been used 
for decades in dentistry for its analgesic properties. Several recent papers reported the anti-diabetic, anti-inflammatory (due to 
antioxidant activity), vasodilative, anticancer, anesthetic, antibacterial, antiviral [12], and cytoprotective of the gastric mucosa [13-
16] activities of clove. Furthermore the utility of clove oil as a penetration enhancer, in vitro and in vivo, has been demonstrated [17]. 
Eugenol is a very promising candidate for versatile applications, and the design of a new prodrug based on the pharmacological 
effects of eugenol could be beneficial.
In literature several studies report the pharmacological activity of the direct-ibuprofen eugenol prodrug (IEE) without improve 
the chemical-physical properties [11,18,19]. Zhao et al. [10] synthesized the ibuprofen eugenol ester (IEE), a virtually non soluble 
highly lipophilic drug, with the aim to reduce the common side effects caused by traditional NSAIDs. The IEE was trapped in a 
microemulsion to increase the water solubility of the preparation.
EU eugenol, IBU ibuprofene, EDC (1,3-ethyl-diaminopropyl carbodiimide hydrochloride), HOBT (N-hydroxybenzotriazole), 
TFA (trifluoroacetic acid), Pepsin from porcine gastric mucosa, powder, ≥250 units/mg solid, Plasma from mouse were purchased 
from Sigma-Aldrich. Polyethylene glycol diOH-PEG (PEG) (MW = 6000 Da), N,N’-disuccinimidyl carbonate, succinic anhydride, 
1,3-diaminopropane, DCC (N,N’dicyclohexylcarbodiimide), DMAP (4-dimethylaminopyridine) and acetonitrile were purchased 
from Fluka (Buchs, Switzerland). All the organic solvents were dried over 4 Å molecular sieves.
The spectrophotometric UV/VIS analysis was performed on a Helios β UNICAM spectrophotometer. 
Spectral analysis
The objective of the present paper is s the synthesis of the prodrug EU-PEG-IBU in order to achieve many advantages related to 
synergistic analgesic and anti-inflammatory effects and to reduction of GI irritation without adverse reactions on their bioactivity 
and to the improvement the poor water solubility of the compounds.
Furthermore, studies in vitro on the release of the parent drugs from this double prodrug in various media, indicate that the adduct 
may be sufficiently stable to pass intact the gastrointestinal tract and release into the circulation eugenol and ibuprofen.
Materials
1H-NMR spectra were recorded on a Jeol EX400 spectrometer in DMSO-d6 using tetramethylsilane (TMS) as internal standard (δ 
= 0.0 ppm). 
ElectroSpray Ionization (ESI) mass spectra were obtained on a PE-API 1 spectrometer by infusion of a solution of the polymeric 
sample in a 1:1 solution of CH3OH/CH3COONa 5% (ionising potential: 5600 V; infusion 0.1 mL/h; curtain gas N2, 1.2 L/min; 
nebulizing gas, air 0.6 L/min).
1H-NMR and mass spectrometry (ESI-MS and/or MALDI-TOF) data fully confirm the signal assignments and structure of the 
materials. 
Methods
HPLC analyses were carried out with a Perkin-Elmer HPLC connected to a variable-wavelength UV detector. A LiChrosorb RP18 
column (5 μm, 250 mm x 4.6 mm i.d., Perkin-Elmer) was used. 
RP-HPLC analysis
HPLC analysis for EU and IBU were carried out according to the method described by Zhao et al. with some modifications [20]. A 
mixture of water – acetonitrile – trifluoroacetic acid - tetrahydrofuran (23:55:2:2 v/v), was employed as mobile phase, the detection 
wavelength was 230 nm and the flow rate was 1 mL/min. Quantification was performed on the basis of linear calibration plot of 
peak area against concentration. Each curve is based on seven concentrations of the standard. Identification of the drugs was made 
by comparison of the retention times with those of pure standard. 
The amount of free NH2 was calculated using the colorimetric TNBS test [21]. The TNBS analysis was made on 2 mg samples of 
different compounds, accurately weighted and added to a 10 ml flask with 9 ml of borate buffer 0.1 M (pH 9.3) and with 0.25 ml of 
a 0.03 M solution of TNBS in the same buffer. The volume was adjusted to 10 ml and after 30 min the absorbance at 421 nm (ε = 
12850) gave the amount of free NH2 groups.
TNBS test
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Synthesis of compound 1: The orthogonally protected diamino PEG 1 was thus synthesized according to a method described by 
Bonora et al. [22]. 
1H-NMR (DMSO-d6): δ = 7.32 ppm (m; 5H, Ar-H), 7.17 (m; 3H, NH-CO-O), 4.99 (s; 2H, CH2-Ph), 4.02 (m; 4H, CH2-O-CO-NH), 
3.53-3.32 (m; 545H, PEG), 2.97 (m; 6H, CH2-NH-CO-O), 1.51 (m; 4H, CH2-CH2-CH2).
Synthesis of compound 2: Cbz-NH(CH2)3NH-CO-O-PEG-O-CO-NH(CH2)3-NH2 1 (1 eq) was coevaporated with 50 ml of 
anhydrous dichloromethane (x2) and dried using a rotary pump; this PEG-derivative was then dissolved in the minimum amount 
of CH2Cl2 (10 ml) and then reacted with IBU (3 eq), by addition of EDC (3 eq) and HOBT (3 eq), keeping pH around 8.5 (TEA). 
The solution was stirred for 18 h at room temperature, precipitated with 50 ml of diethyl ether in an ice-bath and filtered on a Gooch 
3, washed with diethyl-ether and then recrystallized from 100 ml of hot/cold ethanol. The final product (2) was characterized by 
1H-NMR spectroscopy and the amount of free NH2 was calculated using the colorimetric TNBS test. The absence of the free drug 
in the adduct was confirmed by RP-HPLC. The content of linked drug in the conjugate was evaluated by RP-HPLC, on the basis of 
the release of IBU in alkaline media after 15 min at 80 °C. This was found to be 100% (w/w).
1H-NMR (DMSO-d6): δ = 7.88 ppm (brs; 1H, NH), 7.34 [m; 5H, Ar H-(Cbz)], 7.21 (m; 4H, Ar H-IBU, J = 7.51, 8.06 Hz], 7.05 
(m; 3H, 3 NH-CO-O, J = 8.04 Hz), 5.01 [s; 2H, -CH2-Ph (Cbz)], 4.03 [m; 4H, -CH2OCONH (PEG)], 3.53-3.32 [brs, 546H, (CH2-
CH2-O)n-PEG, CH-CH3-IBU], 2.90-3.05 (m; 8H, 3 CH2NHCOO, CH2NHCO), 2.38 [d; 2H, CH2CH(CH3)2-IBU, J = 7.14Hz], 1.79 
[m; 1H, CH(CH3)2-IBU], 1.50 (m; 4H, CH2CH2NHCO), 1.29 [d: 3H, CH-(CH3)-IBU, J = 6.71 Hz], 0.85 [dd; 6H, CH(CH3)2-CH-
IBU, J = 6.56 Hz].
Synthesis of compound 3: The compound (2) thus obtained was then dissolved in 10 ml of methanol, added of 5% Pd/C (in 
a quantity equal to 10% by weight on the substrate) and HCl till pH 2, and stirred at room temperature and under hydrogen 
atmosphere for 16 h. The catalyst was then filtered off through celite and precipitated with 100 ml of diethyl ether in an ice-bath 
and filtered on a Gooch 3, washed with diethyl-ether and then recrystallized from 100 ml of hot/cold ethanol. The conjugated 
NH2-linker-PEG-linker-IBU (1 eq), once deprotected following the general procedure described above, was dissolved in 10 ml 
of anhydrous dichloromethane, added of succinic anhydride (5 eq) and DMAP (2.5 eq). The solution was left stirring at room 
temperature for 16 h, precipitated with 80 ml of diethyl ether in an ice-bath and filtered on a Gooch 3, washed with diethyl-ether 
and then recrystallized from 100 ml of hot/cold ethanol. The final product (3) was characterized by 1H-NMR spectroscopy.
Yield 40%.
Yield 95%.
Yield 95%.
1H-NMR (DMSO-d6): δ = 7.90 ppm (brs; 2H, NH),7.22 ppm [m; 4H, ArH-IBU, J = 7.50, 8.05 Hz], 7.06 (m; 2H, 2 NH-COO, J 
= 7.9 Hz), 4.02 [m; 4H, 2 CH2-OCONH (PEG)], 3.54-3.33 [m; 546H, (CH2-CH2-O)n-PEG, CH-CH3-IBU], 2.85-3.10 [m; 10H, 2 
CH2NHCOO, 2 CH2NHCO, CH2COOH), 2.41 [d; 2H, CH2CH(CH3)2-IBU, J = 7.13 Hz], 2.32 [t; 2H, CH2CONH], 1.82 [m; 1H, 
CH(CH3)2-IBU], 1.50 (m; 4H, CH2CH2NHCO), 1.29 (d; 3H, CH-(CH3)-IBU, J = 7.32 Hz], 0.88 (dd; 6H, (CH3)2-CH-IBU, J = 6.59 
Hz].
Synthesis of compound 4: The compound 3 (1 eq) was coevaporated with 50 ml of anhydrous dichloromethane (2x) and dried 
under high vacuum; this PEG-derivative was then dissolved in the minimum amount of anhydrous dichloromethane (8 ml) and 
then reacted with EU (10 eq), by addition of DCC (5 eq) and DMAP (5 eq). The solution was left stirring for 18 h at room 
temperature under argon atmosphere, precipitated with 80 ml of diethyl ether in an ice-bath and filtered on a Gooch 3, washed 
with diethyl ether and then recrystallized from 100 ml of hot/cold ethanol. The final product (4) was characterized by 1H-NMR 
spectroscopy. 
Yield 94%.
1H-NMR (DMSO-d6): δ = 7.92 ppm (brs; 2H, NH), 7.27 [m; 4H, ArH-IBU, J = 7.51, 8.06 Hz], 7.08 (m; 2H, 2 NHCOO, J = 7.8 
Hz), 6.95 (m; 1H, Ar-H-EU), 6.70-6.75 (m; 2H, ArH-EU, J = 0.6 Hz), 5.90-6.10 (m; 1H, CH-CH=CH2-EU), 5.06, 5.18 (dd, 2H, 
CH-CH=CH2-EU, J = 1.5, 1.4 Hz), 4.05 (m; 4H, 2CH2-OCONH (PEG)], 3.80 (s; 3H, CH3-O-EU), 3.54-3.34 [m; 548H, (CH2-
CH2-O)n-PEG, CH-CH3-IBU, CH2CH=CH2-EU], 2.90-3.10 (m; 10H, 2CH2NHCOO, 2CH2NHCO, CH2COOH), 2.60 [t; 2H, 
CH2CONH), 2.39 [d; 2H, -CH2CH(CH3)2-IBU, J = 7.47 Hz], 1.79 [(m; 1H, CH(CH3)2-IBU], 1.49 (m; 4H, CH2CH2NHCO), 1.29 [d; 
3H, -CH(CH3)-IBU, J = 7.2 Hz], 0.85 [dd; 6H, (CH3)2-CH-IBU, J = 6.60 Hz].
In vitro release studies 
Conjugate stability in simulated extra-cellular fluid and in simulated gastric medium: The study was carried out incubating the 
compound 4 (5mg/ml), in phosphate buffer solution (10 mM NaH2PO4, 0.15 M NaCl) pH 7.4, and artificial gastric juice (2 g NaCl, 
3.2 g pepsin powder, 80ml HCl 1 M in 1 l of water) pH 1.2. The solutions were incubated at 37 ± 0.1 °C and sampled by RP-HPLC 
analysis at schedule times on the basis of formation of free EU and IBU. The quantity of EU and IBU released by hydrolysis was 
quantified with the HPLC method previously described. Every experiment was repeated in triplicate.
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Conjugate stability in plasma: The study was carried out incubating the compound 4 (5mg/ml) in mouse plasma at 37 ± 0.1 °C for 
24 h. At scheduled times samples of 100 µl were collected and 900 µl of cold ACN were added to each samples. After centrifugation 
at 12,000 rpm for 3 min, 500 µl of supernatant was freeze-dried. The obtained residue was dissolved with 50 µl of mobile phase and 
analysed by RP-HPLC analysis as reported above. Every experiment was repeated in triplicate.
IBU: EI-MS (70 eV.): m/z = 206 [M, 27%]+, 191 [M-CH3, 11%]+, 161 [M-CO2H, 100%]+.
EU: EI-MS (70 eV.): m/z = 164 [M, 100%]+, 149 [M-CH3, 22%]+, 137 [M-CH=CH2, 18%]+, 133 [M-OCH3, 20%]+, 91 [M-C6H5-CH2, 
15%]+, 77 [M-C6H5-CH2, 14%]+.
In this study a double PEG-drugs derivative, EU-PEG-IBU, was prepared and used as polymeric carrier to enhance the solubility 
and to minimize gastrointestinal side effects of ibuprofen.
Results and discussions
The synthesis of mixed conjugate was achieved by a derivative of the PEG polymer, whose hydroxylic terminals are selectively and 
reversibly protected groups with different sensitivity to removal (orthogonal protection). The polymeric derivative Cbz-linker-
PEG-linker-NH2 (1) was as described by Campaner et al. [22]. This selectively end-modified polymer derivative can be easily 
conjugated at its extremities with two different molecules, as requested for our purposes. Scheme 1 shows the synthetic strategy for 
the preparation of Cbz-linker-PEG-linker-NH2 (1).
Scheme 1: Scheme of synthesis of Cbz-linker-PEG-linker-NH2
The polymeric derivative selectively modified (1) was used to bind covalently to its ends the drugs ibuprofen and eugenol. Ibuprofen 
was linked through an amide bond while eugenol trough an ester bond.
Scheme 2 shows the synthetic strategy for the preparation of the final adducts eugenol-linker-PEG-linker-ibuprofen (4). The 
reaction between the carboxyl group of IBU and the free amino group of the modified polymer (1) led to the synthesis of the 
compound (2) Cbz-linker-PEG6000-linker-IBU by a stable amide linkage. IBU was added under stirring, to a solution of (1) in ACN, 
in the presence of EDC, HOBT, as coupling agents, and TEA. The HOBT reduced racemization during the synthesis of the amidic 
bond. The product was obtained with a yield of 95%, after precipitation in Et2O, filtration and recrystallization from EtOH hot/
cold. The coupling was achieved using an excess amount of IBU. The success of the reaction was confirmed by the colorimetric 
TNBS test, evaluating the disappearance of the free amino groups of the compound (2). The TNBS (2,4,6-trinitrobenzene sulfonic 
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Figure 1: Structure of H2N-linker-PEG6000-linker-IBU (2a)
The conjugation of eugenol by an ester bond to the activated polymer, NH2-linker-PEG-linker-IBU, requires the presence of a 
carboxylic group. In order to introduce the terminal carboxyl group was used succinic anhydride, since it ensures an excellent 
degree of functionalization. Furthermore, succinic acid is often used as a spacer arm between the drug and polymer [23-25].
The reaction was conducted in dichloromethane in presence of a large excess of succinic anhydride and DMAP as catalyst (Scheme 
1). The carboxylate product (3) was obtained with a yield of 95%, after precipitation in Et2O, filtration and recrystallization from 
EtOH hot/cold. The subsequent esterification reaction between the carboxyl group of the activated polymer (3) and the phenolic 
hydroxyl group of eugenol allowed to obtain the desired adduct (4). The conjugation was carried out in a single step by adding 
eugenol, under stirring, to a solution of HOOC-linker-PEG6000-linker-IBU (3) in ACN in the presence of DCC and DMAP, 
respectively (Scheme 2). The adduct (4) was obtained with a yield of 94%, after precipitation in Et2O, filtration and recrystallization 
from EtOH hot/cold. The absence of the free EU in the adduct was confirmed by RP-HPLC. The content of linked drugs in the 
conjugate was evaluated by RP-HPLC, on the basis of the release of IBU and EU in alkaline media after 15 min at 80 °C. This was 
found to be 100% (w/w).The 1H-NMR spectrum (Figure 2) shows the set of expected signals. In particular, the signals at 7.92 and 
7.08 ppm (J = 7.8 Hz) are due to the two amidic protons and two urethanes protons of (4), respectively. The singlet at 3.80 ppm 
(CH3O), together with the double doublet at 5.06 and 5.18 ppm (CH-CH=CH2,  J = 1.5, 1.4 Hz) confirm the linkage with eugenol 
and the efficient synthetic route.
acid) is a highly sensitive and rapid chemical used for primary amines generating a highly chromogenic product that can be readily 
measured at 421 nm. The results of the TNBS assay indicated a derivatization equal to 0 moles of NH2 to moles of (2), versus 0.98 
moles of NH2 to moles of (1). In addition, the 1H-NMR spectrum showed the set of expected signals, in particular the multiplet 
at 7.21 ppm is due to the aromatic protons ascribed to ibuprofen, while the doublet at 1.35 ppm is due to the methyl group of IBU 
adjacent to the amide group (J = 7.34 Hz). The typical chemical shift between 3.53-3.32 ppm of the methylenic protons of PEG and 
the signals at 7.05 (m; 3H, 3NH-urethane) confirm the synthesis of the conjugate (2) characterized by a stable amide like linkage.
Scheme 2: Scheme of synthesis of eugenol-linker-PEG-linker-ibuprofen
The next step was the deprotection of Cbz protected the amino group of (2) and the reaction with succinic anhydride to obtain 
the compound (3) with a terminal carboxyl functionality. The removal of the Cbz has required careful control of the reaction 
conditions to avoid the undesired detachment of the linker because of the presence of NH2 group free, nucleophilic function, 
at its end. In fact, due to a probable attack intramolecular and / or intermolecular, was observed a significant reduction of the 
total amine functionality in neutral conditions. Consequently, the hydrogenolysis of the Cbz group was performed under acidic 
conditions, carefully optimized, since the protonation of the free amino function has avoided any side reaction and allowed a 
complete recovery. The full release was confirmed by the TNBS test, evaluating the presence of free amino groups in the compound 
NH2-linker-PEG-linker-IBU, (Figure 1) it detects a derivatization equal to 0.98 moles of -NH2 per mole of compound. The 1H-NMR 
spectrum shows the disappearance of the signals at 7.34 ppm and 5.01 ppm relative to the Cbz group.
In the final conjugate EU-linker-PEG6000-linker-IBU (4), EU and IBU molecules were linked through an ester and an amide bond, 
respectively; since the cleavage of these bonds was likely to occur in plasma, EU and IBU molecules were released.
The hydrolysis rate of the conjugate was studied in vitro in a phosphate buffer solution pH 7.4, and in artificial gastric juice pH 1.2.
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Figure 2: 1H-NMR in DMSO-d6 di EU-linker-PEG6000-linker-IBU (4)
Figure 3 shows that the hydrolysis rate of the EU-linker-PEG6000-linker-IBU (4) in phosphate buffer solution pH 7.4, at 37 °C is 
related to the type of bond; about 50% of EU and less than 2 % of IBU are released from the polymer over 24 h. 
Figure 3: Release of EU and IBU from EU-linker-PEG6000-linker-IBU in phosphate buffer solution pH 7.4 (-), in artificial gastric juice pH 1.2 (------) at 37 ± 0.1 °C
Figure 3 depicts, also, the hydrolytic behavior for the same conjugate in artificial gastric fluid (0.32% of gastric protease) at pH 1.2, 
37 °C. Approximately less than 4.8 % of IBU and 15% of EU were released over 6 h. On the basis of the above data, the hydrolytic 
stability is also good in gastric juice.
O
NH
H
N
O
O-PEG-O
O
H
NHN
OO
O
O
The degradation of (4) was followed by RP-HPLC analysis of the released free drugs. 
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Figure 4: Release of EU and IBU from EU-linker-PEG6000- linker-IBU in mouse plasma at 37 ± 0.1 °C, ■ EU,  IBU
Conclusion
On the basis of our previous investigations we studied this new bifunctional, multimeric PEG-based support as a new drug delivery 
system where two different and synergic drugs were linked on the same biocompatible polymeric support. According to the 
pharmacodynamic analysis the stability of this new PEG-bis conjugate in artificial gastric fluid was confirmed, while a slow release 
of the drugs in plasma mouse was also observed. 
The EU-linker-PEG6000-linker-IBU therefore, was almost hydrolytically stable in phosphate buffer pH 7.4 (no hydrolysis for IBU), 
and in simulated gastric medium showing good resistance in the stomach acidic medium.
The macromolecular prodrug ability to release the free drugs was also evaluated in mouse plasma. More than 95% of linked EU and 
87% of IBU were released from the polymeric conjugate within 24 h (Figure 4). This indicates that the macromolecular conjugate 
may a good substrate for the plasma enzymatic complex and its capacity to deliver free and active drugs in a prolonged manner. 
The structure of released EU and IBU was confirmed by mass spectrometry analysis. The molecular ion at m/z = 164 confirmed 
the presence of EU and the fragments at m/z = 149 and 91 were due to the loss of a methyl and of C2H3 group; respectively. The 
molecular ion at m/z = 206 confirmed the presence of IBU and the fragments at m/z = 191 and 161 were due to the loss of a methyl 
and a carboxyl group; respectively.
Graphical abstract
Eugenol and ibuprofene were covalently bound to bi-functionalized PEG, used as molecular carrier of drugs, and the release 
kinetics of the two bioactive molecules was studied in vitro in buffer solutions and in mouse plasma. The conjugation of two drugs 
having different pharmacological activities led to a mutual prodrug with synergistic and anti-inflammatory effects and reduced GI 
irritation.
The conjugation of eugenol with ibuprofen as a reversible prodrug leads to many advantages including stabilization, reduction of 
irritation, unpleasant smell and versatility of usage. In addition, the biotransformation of the prodrugs into the parent compounds 
at its target site or sites of activity might be used to achieve rate and time controlled drug delivery of the active entities. 
Pharmacological studies will give further data about the most convenient use of these PEGylated molecules in therapy. The 
conjugation of two drugs having different pharmacological activities should lead to a mutual prodrug with synergistic and anti-
inflammatory effects and reduced GI irritation.
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